Segunda parte | 27 OCT 04
Quimioprevención del cáncer
Esta segunda parte trata sobre la quimioprevención de diferentes cánceres: mama, colorrectal, cabeza y cuello, pulmón, vejiga, próstata, piel y cérvix.
Autor/a: Dres. Tsao AS, Kim ES, Hong WK. CA Cancer J Clin. 2004 May-Jun;54(3):150-80.
Desarrollo
61. Brennan JA, Mao L, Hruban RH, et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 1995; 332: 429-435.
62. Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992; 256: 102-105.
63. Sidransky D, Mikkelsen T, Schwechheimer K, et al. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992; 355: 846-847.
64. Mao L, Hruban RH, Boyle JO, et al. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 1994; 54: 1634-1637.
65. Zhang Z, Nakamura M, Taniguchi E, et al. Late occurrence of K-ras gene mutations in the pathogenesis of squamous cell carcinoma of the lung: analysis in sputum. Anal Quant Cytol Histol 1996; 18: 501-502.
66. Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997; 3: 515-522.
67. Rusch V, Mendelsohn J, Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev 1996; 7: 133-141.
68. Lippman SM, Lee JS, Lotan R, et al. Biomarkers as intermediate end points in chemoprevention trials. J Natl Cancer Inst 1990; 82: 555-560.
69. Simpson JF, Page DL. Pathology of preinvasive and excellent prognosis breast cancer. Curr Opin Oncol 2001; 13: 426-430.
70. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-532.
71. Toyota M, Shen L, Ohe-Toyota M, et al. Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res 2000; 60: 4044-4048.
72. Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000; 6: 1702-1710.
73. van Houten VM, Tabor MP, van den Brekel MW, et al. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. J Pathol 2002; 198: 476-486.
74. Takahashi T, Nau MM, Chiba I, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989; 246: 491-494.
75. Mitsudomi T, Steinberg SM, Nau MM, et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992; 7: 171-180.
76. Sugio K, Kishimoto Y, Virmani AK, et al. K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res 1994; 54: 5811-5815.
77. Hirano T, Franzen B, Kato H, et al. Genesis of squamous cell lung carcinoma. Sequential changes of proliferation, DNA ploidy, and p53 expression. Am J Pathol 1994; 144: 296-302.
78. Leffell DJ. The scientific basis of skin cancer. J Am Acad Dermatol 2000; 42: 18-22.
79. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372: 773-76.
80. Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998; 19: 723-729.
81. Peus D, Vasa RA, Meves A, et al. H2O2
62. Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992; 256: 102-105.
63. Sidransky D, Mikkelsen T, Schwechheimer K, et al. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992; 355: 846-847.
64. Mao L, Hruban RH, Boyle JO, et al. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 1994; 54: 1634-1637.
65. Zhang Z, Nakamura M, Taniguchi E, et al. Late occurrence of K-ras gene mutations in the pathogenesis of squamous cell carcinoma of the lung: analysis in sputum. Anal Quant Cytol Histol 1996; 18: 501-502.
66. Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997; 3: 515-522.
67. Rusch V, Mendelsohn J, Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev 1996; 7: 133-141.
68. Lippman SM, Lee JS, Lotan R, et al. Biomarkers as intermediate end points in chemoprevention trials. J Natl Cancer Inst 1990; 82: 555-560.
69. Simpson JF, Page DL. Pathology of preinvasive and excellent prognosis breast cancer. Curr Opin Oncol 2001; 13: 426-430.
70. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-532.
71. Toyota M, Shen L, Ohe-Toyota M, et al. Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res 2000; 60: 4044-4048.
72. Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000; 6: 1702-1710.
73. van Houten VM, Tabor MP, van den Brekel MW, et al. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. J Pathol 2002; 198: 476-486.
74. Takahashi T, Nau MM, Chiba I, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989; 246: 491-494.
75. Mitsudomi T, Steinberg SM, Nau MM, et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992; 7: 171-180.
76. Sugio K, Kishimoto Y, Virmani AK, et al. K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res 1994; 54: 5811-5815.
77. Hirano T, Franzen B, Kato H, et al. Genesis of squamous cell lung carcinoma. Sequential changes of proliferation, DNA ploidy, and p53 expression. Am J Pathol 1994; 144: 296-302.
78. Leffell DJ. The scientific basis of skin cancer. J Am Acad Dermatol 2000; 42: 18-22.
79. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372: 773-76.
80. Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998; 19: 723-729.
81. Peus D, Vasa RA, Meves A, et al. H2O2
Comentarios
Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024